Hannah E Scales1, Michelle Ierna2, Karen M Smith2, Kirsty Ross3, Gordon R Meiklejohn2, Janet C Patterson-Kane4, Iain B McInnes4, James M Brewer4, Paul Garside4, Pasquale Maffia5. 1. Centre for Immunobiology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, MD Biosciences. 2. MD Biosciences. 3. Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde, Glasgow, UK and. 4. Centre for Immunobiology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow. 5. Centre for Immunobiology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Department of Pharmacy, University of Naples Federico II, Naples, Italy Pasquale.Maffia@glasgow.ac.uk.
Abstract
OBJECTIVE: In the present study we evaluated the use of four commercially available fluorescent probes to monitor disease activity in murine CIA and its suppression during glucocorticoid therapy. METHODS: Arthritis was induced in male DBA/1 mice by immunization with type II collagen in Complete Freund's Adjuvant, followed by a boost of collagen in PBS. Four fluorescent probes from PerkinElmer in combination [ProSense 750 fluorescent activatable sensor technology (FAST) with Neutrophil Elastase 680 FAST and MMPSense 750 FAST with CatK 680 FAST] were used to monitor disease development from day 5 through to day 40 post-immunization. Fluorescence generated in vivo by the probes was correlated with clinical and histological score and paw measurements. RESULTS: The fluorescence intensity emitted by each probe was shown to correlate with the conventional measurements of disease. The highest degree of correlation was observed with ProSense 750 FAST in combination with Neutrophil Elastase 680 FAST; these probes were then used to successfully assess CIA suppression during dexamethasone treatment. CONCLUSION: We have demonstrated that longitudinal non-invasive duplexed optical fluorescence imaging provides a simple assessment of arthritic disease activity within the joints of mice following the induction of CIA and may represent a powerful tool to monitor the efficacy of drug treatments in preclinical studies.
OBJECTIVE: In the present study we evaluated the use of four commercially available fluorescent probes to monitor disease activity in murine CIA and its suppression during glucocorticoid therapy. METHODS: Arthritis was induced in male DBA/1 mice by immunization with type II collagen in Complete Freund's Adjuvant, followed by a boost of collagen in PBS. Four fluorescent probes from PerkinElmer in combination [ProSense 750 fluorescent activatable sensor technology (FAST) with Neutrophil Elastase 680 FAST and MMPSense 750 FAST with CatK 680 FAST] were used to monitor disease development from day 5 through to day 40 post-immunization. Fluorescence generated in vivo by the probes was correlated with clinical and histological score and paw measurements. RESULTS: The fluorescence intensity emitted by each probe was shown to correlate with the conventional measurements of disease. The highest degree of correlation was observed with ProSense 750 FAST in combination with Neutrophil Elastase 680 FAST; these probes were then used to successfully assess CIA suppression during dexamethasone treatment. CONCLUSION: We have demonstrated that longitudinal non-invasive duplexed optical fluorescence imaging provides a simple assessment of arthritic disease activity within the joints of mice following the induction of CIA and may represent a powerful tool to monitor the efficacy of drug treatments in preclinical studies.
Authors: A Mitra; S Kundu-Raychaudhuri; C Abria; A Rona; A J Chaudhari; S P Raychaudhuri Journal: Clin Exp Immunol Date: 2017-02-24 Impact factor: 4.330
Authors: Beth Friedman; Michael A Whitney; Elamprakash N Savariar; Christa Caneda; Paul Steinbach; Qing Xiong; Dina V Hingorani; Jessica Crisp; Stephen R Adams; Michael Kenner; Csilla N Lippert; Quyen T Nguyen; Monica Guma; Roger Y Tsien; Maripat Corr Journal: Arthritis Rheumatol Date: 2017-11-29 Impact factor: 10.995
Authors: Tuula Peñate Medina; Jan Philip Kolb; Gereon Hüttmann; Robert Huber; Oula Peñate Medina; Linh Ha; Patricia Ulloa; Naomi Larsen; Arianna Ferrari; Magdalena Rafecas; Mark Ellrichmann; Mariya S Pravdivtseva; Mariia Anikeeva; Jana Humbert; Marcus Both; Jennifer E Hundt; Jan-Bernd Hövener Journal: Front Immunol Date: 2021-06-24 Impact factor: 7.561
Authors: Maria A Lim; Brenton Louie; Daniel Ford; Kyle Heath; Paulyn Cha; Joe Betts-Lacroix; Pek Yee Lum; Timothy L Robertson; Laura Schaevitz Journal: Front Pharmacol Date: 2017-11-14 Impact factor: 5.810